Article
Nutrition & Dietetics
Jing Feng, Qi Feng, Yueying Chen, Tian Yang, Saiming Cheng, Yuqi Qiao, Jun Shen
Summary: This study investigated the correlation between R2* and inflammation and developed a non-invasive nomogram based on R2* to identify SLR to infliximab in patients with CD.
FRONTIERS IN NUTRITION
(2022)
Article
Nutrition & Dietetics
Mia Bendix, Anders Dige, Soren Peter Jorgensen, Jens Frederik Dahlerup, Bo Martin Bibby, Bent Deleuran, Jorgen Agnholt
Summary: Seven-week high-dose vitamin D treatment reduces the need for later infliximab dose escalation and decreases inflammatory markers in patients with active Crohn's disease.
Article
Gastroenterology & Hepatology
Ashish Srinivasan, Peter De Cruz, Melissa Sam, Catherine Toong, Daniel R. van Langenberg
Summary: This study compared two different strategies, repeat infliximab induction and shorter dose interval, for addressing secondary loss of response in patients with inflammatory bowel disease. The study found that both strategies had similar clinical response rates, but they resulted in distinct pharmacokinetic profiles.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Eun Sil Kim, Yiyoung Kwon, Yon Ho Choe, Mi Jin Kim
Summary: This study evaluated the relationship between free and total antibodies-to-infliximab (ATIs), trough levels (TLs) of IFX, and the response to dose intensification in pediatric patients with Crohn's disease (CD). The results showed that free ATIs had a negative impact on the course of CD and were a potential reliable biomarker for predicting the effect of dose intensification in patients with loss of response to IFX.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2023)
Article
Medicine, Research & Experimental
Yueying Chen, Feng Jing, Yang Tian, Qiao Yuqi, Shen Jun
Summary: This study aimed to develop a novel nomogram based on bioelectrical impedance analysis (BIA) indexes and laboratory markers to predict secondary loss of response (SLR) to infliximab in biologically naive Crohn's disease patients. The nomogram included predictors such as hemoglobin, albumin, serum iron, and BIA scores, showing significant discrimination, calibration, and net clinicalbenefit within certain risk probability ranges. Internal validation confirmed the robustness of the nomogram with high accuracy.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Review
Gastroenterology & Hepatology
Edo H. J. Savelkoul, Pepijn W. A. Thomas, Lauranne A. A. P. Derikx, Nathan den Broeder, Tessa E. H. Romkens, Frank Hoentjen
Summary: Loss of response to infliximab or adalimumab in ulcerative colitis occurs frequently, with an annual rate of 10% for infliximab and 13% for adalimumab. Dose escalation rates were higher than loss of response, with 72% and 52% regaining clinical benefit for infliximab and adalimumab, respectively. Uniform definitions are needed for more robust evaluations.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Immunology
Yueying Chen, Hanyang Li, Jing Feng, Shiteng Suo, Qi Feng, Jun Shen
Summary: The study successfully developed a radiomic nomogram to predict secondary loss of response to IFX in CD patients, which showed high accuracy and clinical benefit in decision-making for physicians.
JOURNAL OF INFLAMMATION RESEARCH
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Chen Yueying, Feng Jing, Feng Qi, Shen Jun
Summary: A magnetic resonance enterography-based model was constructed in this study to predict the risk of loss of response to infliximab (IFX) in bio-naive patients with Crohn's disease (CD), providing an effective tool for the early estimation of treatment response before biological intervention.
EUROPEAN RADIOLOGY
(2023)
Article
Gastroenterology & Hepatology
Ruben J. Colman, Ye Xiong, Tomoyuki Mizuno, Jeffrey S. Hyams, Joshua D. Noe, Brendan Boyle, Geert R. D'Haens, Johan van Limbergen, Kelly Chun, Jane Yang, Michael J. Rosen, Lee A. Denson, Alexander A. Vinks, Phillip Minar
Summary: This study evaluated the impact of ATI on infliximab clearance and loss of response, finding that even low levels of ATI can affect drug clearance. The data suggest that dose optimization for low-level ATI can improve infliximab clearance and prevent loss of response.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Gastroenterology & Hepatology
Eun Sil Kim, Sujin Choi, So Yoon Choi, Ji Hyung Park, Byung-Ho Choe, Soo-Youn Lee, Mi Jin Kim, Yon Ho Choe, Ben Kang
Summary: NUDT15 intermediate metabolisers are associated with lower loss of response in pediatric patients with CD treated with IFX and AZA combination therapy.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Gastroenterology & Hepatology
Hongsheng Yang, Bingyang Li, Qin Guo, Jian Tang, Bo Peng, Ni Ding, Miao Li, Qingfang Yang, Zicheng Huang, Na Diao, Xia Zhu, Jun Deng, Huili Guo, Pinjin Hu, Kang Chao, Xiang Gao
Summary: Ustekinumab is effective in treating CD and UC, with a risk of LOR and dose escalation of 21% and 25% respectively in CD patients. After dose escalation, 58% of patients regain clinical response. Limited data is available for LOR in UC patients, but dose escalation has shown a risk of 18% and a remission rate of 58%.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Gastroenterology & Hepatology
Ashish Srinivasan, Robert Gilmore, Daniel van Langenberg, Peter De Cruz
Summary: Anti-TNF dose intensification is clinically effective in patients with Crohn's disease, particularly within the first 6 months. However, a proportion of patients may fail to demonstrate short-term and/or sustained clinical response. Hence, clinical reassessment remains important, particularly beyond 6 months of dose intensification.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Jacob E. Ollech, Inessa Normatov, Noam Peleg, Jingzhou Wang, Shivani A. Patel, Victoria Rai, Yangtian Yi, Jorie Singer, Sushila R. Dalal, Atsushi Sakuraba, Russell D. Cohen, David T. Rubin, Joel Pekow
Summary: Shortening the ustekinumab dose interval to 4 weeks improved clinical and biological indices of disease activity in patients with Crohn's disease who did not respond to the standard dose every 8 weeks. This approach could be effective and safe for patients who lose response to the standard dose of ustekinumab.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Gloria S. Z. Tun, Kerry Robinson, Laura Marshall, Alison Wright, Laura Thompson, Graeme Wild, Ravishankar Sargur, Alenka J. Brooks, Melissa F. Hale, Thean S. Chew, Alan J. Lobo
Summary: DE strategy in selected patients receiving infliximab is associated with increased drug levels and reduced ATI positivity, and approximately 70% of patients achieve clinical remission within 6 months.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2022)
Review
Gastroenterology & Hepatology
Hiroshi Nakase, Motohiro Esaki, Fumihito Hirai, Taku Kobayashi, Katsuyoshi Matsuoka, Minoru Matsuura, Makoto Naganuma, Masayuki Saruta, Kiichiro Tsuchiya, Motoi Uchino, Kenji Watanabe, Tadakazu Hisamatsu, TRADE Consensus Grp
Summary: The study aimed to develop specific treatment guidelines for patients with different types of Crohn's disease (CD), including luminal CD, CD with perianal disease or fistula, CD with small bowel stenosis, postoperative CD, and patients who need to reduce or discontinue treatment. The study reviewed relevant studies and utilized a modified Delphi process to reach consensus among specialists. The resulting statements provide guidance on treatment intensification and de-intensification for CD patients.
JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Luigi Gatta, Olga P. Nyssen, Giulia Fiorini, Ilaria Maria Saracino, Matteo Pavoni, Marco Romano, Antonietta Gerarda Gravina, Lucia Granata, Rinaldo Pellicano, Antonio Gasbarrini, Alfredo Di Leo, Giuseppe Losurdo, Francesco Franceschi, Gerardo Nardone, Alba Rocco, Maria Pina Dore, Fabio Farinati, Matteo Ghisa, Massimo Bellini, John Holton, Ignasi Puig, Dino Vaira, Claudio Borghi, Francis Megraud, Colm O'Morain, Javier P. Gisbert
Summary: This study evaluated the effectiveness and safety of empirical first- and second-line treatments for Helicobacter pylori patients. Only quadruple therapies lasting at least 10 days achieved over 90% eradication rates, and high-dose PPI twice daily improved the effectiveness of some treatments.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2023)
Article
Biochemistry & Molecular Biology
Rosario Medina-Medina, Eva Iglesias-Flores, Jose M. Benitez, Sandra Marin-Pedrosa, Isabel Salgueiro-Rodriguez, Clara I. Linares, Sandra Gonzalez-Rubio, Pilar Soto-Escribano, Beatriz Gros, Manuel L. Rodriguez-Peralvarez, Jose L. Cabriada, Maria Chaparro, Javier P. Gisbert, Eduardo Chicano-Galvez, Ignacio Ortea, Gustavo Ferrin, Valle Garcia-Sanchez, Patricia Aguilar-Melero
Summary: Therapy with anti-TNF has transformed the treatment of Crohn's disease, but long-term efficacy is limited and adverse events can occur. This study aimed to find reliable markers to predict response to anti-TNF drugs in Crohn's disease patients. By comparing protein expression profiles in plasma samples, we identified 18 differentially expressed proteins, including vinculin, that may serve as biomarkers for short-term remission. Plasma vinculin levels, along with other factors such as baseline CD Activity Index, corticosteroid induction, and bowel resection, can predict non-short-term remission.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Montse Baldan-Martin, Maria Chaparro, Javier P. Gisbert
Summary: Inflammatory bowel diseases (IBDs) are chronic and inflammatory conditions affecting the gastrointestinal tract. Despite endoscopy being the gold standard test for assessing IBD, it is invasive and uncomfortable for patients. Therefore, non-invasive biomarkers for IBD diagnosis are urgently needed. This review summarizes proteomics and metabolomics studies in animals and humans, identifying urinary biomarkers for IBD diagnosis. Large-scale multi-omics studies with collaboration between clinicians, researchers, and industry are necessary for the development of sensitive and specific diagnostic biomarkers for personalized medicine.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Emily K. Wright, Maria Chaparro, Paolo Gionchetti, Amy L. Hamilton, Julien Schulberg, Javier P. Gisbert, Maria Chiara Valerii, Fernando Rizzello, Peter De Cruz, John C. Panetta, Annelie Everts-van der Wind, Michael A. Kamm, Thierry Dervieux
Summary: This study found that adalimumab drug clearance is a critical factor in determining the therapeutic outcome of Crohn's disease patients. Patients with lower drug clearance showed better endoscopic remission, while drug concentration did not significantly differ between patients in remission and those with recurrence. Sustained clinical remission based on C-reactive protein and lower faecal calprotectin levels were generally associated with lower clearance and higher drug concentration.
JOURNAL OF CROHNS & COLITIS
(2023)
Review
Gastroenterology & Hepatology
Javier P. Gisbert, Maria Chaparro
Summary: The de-escalation of biologic therapy in inflammatory bowel disease (IBD) carries risks and uncertainties and should be tailored to individual patients.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Infectious Diseases
Olga. P. Nyssen, Pietro Pratesi, Miguel. A. Spinola, Laimas Jonaitis, Angeles Perez-Aisa, Dino Vaira, Ilaria Maria Saracino, Matteo Pavoni, Giulia Fiorini, Bojan Tepes, Dmitry. S. Bordin, Irina Voynovan, Angel Lanas, Samuel. J. Martinez-Dominguez, Enrique Alfaro, Luis Bujanda, Manuel Pabon-Carrasco, Luis Hernandez, Antonio Gasbarrini, Juozas Kupcinskas, Frode Lerang, Sinead. M. Smith, Oleksiy Gridnyev, Marcis Leja, Theodore Rokkas, Ricardo Marcos-Pinto, Antonio Mestrovic, Wojciech Marlicz, Vladimir Milivojevic, Halis Simsek, Lumir Kunovsky, Veronika Papp, Perminder. S. Phull, Marino Venerito, Lyudmila Boyanova, Doron Boltin, Yaron Niv, Tamara Matysiak-Budnik, Michael Doulberis, Daniela Dobru, Vincent Lamy, Lisette. G. Capelle, Emilijia Nikolovska Trpchevska, Leticia Moreira, Anna Cano-Catalia, Pablo Parra, Francis Megraud, Colm O'Morain, Guillermo. J. Ortega, Javier. P. Gisbert
Summary: The segmentation of patients into homogeneous groups can improve the effectiveness of eradication therapy. The study aims to determine the most important treatment strategies used in Europe and evaluate the effectiveness of first-line treatments based on year and country. The analysis found that the overall treatment effectiveness increased from 87% in 2013 to 93% in 2022, with the highest effectiveness achieved in 2022 using bismuth-quadruple therapy in Spain. Cluster analysis identified homogeneous treatment groups and assessed the effectiveness of different first-line treatments.
Article
Biochemistry & Molecular Biology
Irene Soleto, Cristina Ramirez, Cristina Gomez, Montse Baldan-Martin, Macarena Orejudo, Jorge Mercado, Maria Chaparro, Javier P. Gisbert
Summary: This study reveals that type 2 conventional DCs (cDC2) in patients with inflammatory bowel disease (IBD) exhibit a heightened migratory profile compared to other DC subsets, potentially highlighting new diagnostic biomarkers or immunomodulatory targets for IBD.
Meeting Abstract
Gastroenterology & Hepatology
J. Burisch, M. Zhao, S. Odes, P. De Cruz, S. Vermeire, C. N. Bernstein, G. G. Kaplan, D. Duricova, D. Greenberg, H. O. Melberg, M. Watanabe, H. S. Ahn, L. Targownik, V. E. H. Pittet, V. Annese, K. Park, K. H. Konstantinos H, M. L. Hoivik, Z. Krznaric, M. Chaparro, E. V. Loftus, P. L. Lakatos, J. P. Gisbert, W. Bemelman, B. Moum, R. B. Gearry, M. D. Kappelman, A. Hart, M. Pierik, J. Andrews, S. Ng, R. D'Inca, P. Munkholm
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
M. Calafat Sard, C. Suria, F. Mesonero, R. de Francisco, C. Yague Caballero, L. de la Pena, A. Hernandez-Camba, A. Marce, B. Gallego, N. Martin-Vicente, M. Rivero, M. Iborra, I. Guerra, M. Carrillo-Palau, L. Madero, B. Burgueno, D. Montfort, G. Torres, M. Teller, J. A. Ferrer Rosique, P. Vega Villaamil, C. Roig, A. Ponferrada, E. Betore Glaria, Y. Zabana, J. P. Gisbert, N. Alcaide, B. Camps, J. Legido, M. Gonzalez Vivo, M. M. Bosca-Watts, I. Perez-Martinez, D. Casas Deza, J. Guardiola, L. Arranz Hernandez, M. Navarro, F. Gomollon, F. Canete, M. Manosa, E. Domenech
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
F. Casellas Jorda, C. Rodriguez, J. P. Gisbert, S. Bernardo, J. Aparicio, I. Tagarro, F. Munoz
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
M. Chaparro, D. Acosta, C. Rodriguez, F. Mesonero, M. Vicuna, M. Barreiro-de Acosta, A. Fernandez-Clotet, A. Hernandez Martinez, M. Arroyo, I. Vera, A. Ruiz-Cerulla, B. Sicilia, M. J. Cabello Tapia, C. Munoz Villafranca, J. Castro-Poceiro, J. Martinez Cadilla, M. Sierra-Ausin, M. Vazquez Moron, E. Montil Miguel, F. Bermejo, V. Royo, M. Calafat, C. Gonzalez-Munoza, E. Leo Carnerero, N. Mancenido Marcos, L. Torrealba, H. Alonso-Galan, M. Benitez, Y. Ber Nieto, M. T. Diz-Lois Palomares, M. J. Garcia, J. F. Munoz, E. M. Armesto Gonzalez, X. Calvet, A. Hernandez-Camba, R. E. Madrigal Dominguez, L. Menchen, J. L. Perez Calle, M. Piqueras, J. P. Gisbert
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
M. Calafat Sard, I. Pascual, P. Nos, J. Barrio, A. Gutierrez, M. D. Martin-Arranz, E. Ricart, F. Gomollon, M. Sierra Ausin, J. M. Huguet, J. Guardiola, I. Vera, P. Varela, E. Iglesias, E. Garcia-Planella, L. de Castro, M. F. Garcia Sepulcre, B. Sicilia, L. Fernandez-Salazar, X. Calvet, F. Munoz, S. Garcia-Lopez, F. Bermejo, L. Ramos, P. Martinez Montiel, R. Lorente, J. L. Cabriada, M. Piqueras, I. Marin-Jimenez, M. Esteve, F. Mesonero, E. Sese, J. P. Gisbert, L. Marquez, D. Busquets, R. Pajares, F. Canete, M. Manosa, E. Domenech
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
P. Sanz Segura, F. Gomollon, S. Garcia Garcia, M. Vela, A. Fernandez-Clotet, R. Munoz, I. Garcia de la Filia, M. Garcia Prada, J. A. Ferrer Rosique, M. J. Garcia, R. de Francisco, L. Arias, J. Barrio, I. Guerra, A. Ponferrada Diaz, J. P. Gisbert, M. Carrillo-Palau, X. Calvet, L. Marquez-Mosquera, B. Gros, F. Canete, D. Monfort, R. E. Madrigal, O. Roncero, V. Laredo, M. Montoro, C. Munoz, B. Lopez-Cauce, R. Lorente, A. Fuentes, P. Vega, D. Martin, J. Nerin de la Puerta, P. Varela, D. Casas-Deza, P. Martinez, R. Pajares, A. J. Lucendo, E. Domenech, S. Garcia-Lopez
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
I. Soleto, A. C. Marin, I. Mora, J. R. Villagrasa, M. Baldan-Martin, C. Ramirez, D. Bernardo, M. Chaparro, J. P. Gisbert
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
I. Soleto, M. Baldan, C. Ramirez, M. Orejudo, S. Garcia, J. Mercado, M. Azkargorta, I. Lloro, L. Ortega Moreno, L. Aldars Garcia, S. Riestra, M. Rivero, A. Gutierrez, I. Rodriguez-Lago, L. Fernandez, D. Ceballos, J. M. Benitez, M. Aguas, I. Baston Rey, F. Bermejo, M. J. Casanova, R. Lorente, Y. Ber, D. Ginard, M. Esteve, F. Elortza, J. P. Gisbert, N. Martin-Cofreces, M. Chaparro
JOURNAL OF CROHNS & COLITIS
(2023)